Propanc Biopharma, Inc. - Common Stock (NQ:PPCB)

1.760 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2026 Add to My Watchlist

Price and Volume

Volume	1,428
Open	1.760
Bid (Size)	1.770 (2,800)
Ask (Size)	1.840 (100)
Prev. Close	1.760
Today's Range	1.760 - 1.760
52wk Range	0.0635 - 2.350
Shares Outstanding	15,859,280
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade

May 20, 2026

Plans to File CTA for Ph. 1b, FIH Study, 30 – 40 Advanced Cancer Patients in ‘26

From Propanc Biopharma, Inc.

Via GlobeNewswire

Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients

May 19, 2026

Provides End-To-End Services for Preclinical & Clinical Projects with Extensive Experience in Decoding Biologics Production

From Propanc Biopharma, Inc.

Via GlobeNewswire

Performance

YTD	+207.9%	+207.9%
1 Month	+1318.2%	+1318.2%
3 Month	+738.1%	+738.1%
6 Month	+104.7%	+104.7%
1 Year	-4.3%	-4.3%

More News

Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results

May 15, 2026

From Propanc Biopharma, Inc.

Via GlobeNewswire

Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

May 13, 2026

From Propanc Biopharma, Inc.

Via GlobeNewswire

Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB

April 17, 2026

From Rosen Law Firm

Via Business Wire

These stocks are moving in today's after hours session ↗

April 17, 2026

Via Chartmill

Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB

April 16, 2026

From The Rosen Law Firm, P.A.

Via Business Wire

Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain

March 24, 2026

From Propanc Biopharma, Inc.

Via GlobeNewswire

Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy

March 12, 2026

From Propanc Biopharma, Inc.

Via GlobeNewswire

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

March 10, 2026

From Propanc Biopharma, Inc.

Via GlobeNewswire

Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

March 03, 2026

From Propanc Biopharma, Inc.

Via GlobeNewswire

Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

February 18, 2026

From Propanc Biopharma, Inc.

Via GlobeNewswire

Wondering what's happening in today's after-hours session? ↗

February 16, 2026

Via Chartmill

Unusual volume stocks in Friday's session ↗

February 06, 2026

Via Chartmill

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market

February 05, 2026

From Propanc Biopharma, Inc.

Via GlobeNewswire

Top movers in Thursday's session ↗

January 29, 2026

Via Chartmill

Thursday's session: gap up and gap down stocks ↗

January 29, 2026

Via Chartmill

These stocks that are showing activity before the opening bell on Thursday. ↗

January 29, 2026

Via Chartmill

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations

January 27, 2026

From Propanc Biopharma, Inc.

Via GlobeNewswire

Which stocks are moving after the closing bell on Friday? ↗

January 23, 2026

Via Chartmill

Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia

January 20, 2026

From Propanc Biopharma, Inc.

Via GlobeNewswire

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer

January 15, 2026

From Propanc Biopharma, Inc.

Via GlobeNewswire

Propanc Biopharma Provides Shareholder Update

January 13, 2026

From Propanc Biopharma, Inc.

Via GlobeNewswire

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

December 04, 2025

From Propanc Biopharma, Inc.

Via GlobeNewswire

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

December 22, 2025

From Propanc Biopharma, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Propanc Biopharma, Inc. - Common Stock publicly traded?

Yes, Propanc Biopharma, Inc. - Common Stock is publicly traded.

What exchange does Propanc Biopharma, Inc. - Common Stock trade on?

Propanc Biopharma, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Propanc Biopharma, Inc. - Common Stock?

The ticker symbol for Propanc Biopharma, Inc. - Common Stock is PPCB on the Nasdaq Stock Market

What is the current price of Propanc Biopharma, Inc. - Common Stock?

The current price of Propanc Biopharma, Inc. - Common Stock is 1.760

When was Propanc Biopharma, Inc. - Common Stock last traded?

The last trade of Propanc Biopharma, Inc. - Common Stock was at 05/20/26 04:00 PM ET

What is the market capitalization of Propanc Biopharma, Inc. - Common Stock?

The market capitalization of Propanc Biopharma, Inc. - Common Stock is 27.91M

How many shares of Propanc Biopharma, Inc. - Common Stock are outstanding?

Propanc Biopharma, Inc. - Common Stock has 28M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.